Does the risk of developing diabetes in hypertensive kidney disease vary with different antihypertensive agents?
Karin Jandeleit-Dahm
Correspondence Baker Heart Research Institute, Commercial Road, Melbourne, Vic 3004, Australia
Email karin.jandeleit-dahm@baker.edu.au
This article has no abstract so we have provided the first paragraph of the full text.
Evidence has recently been accumulating that antihypertensive therapy with RAS inhibitors might retard the development of new-onset diabetes mellitus.1, 2 It has been difficult, however, to assess if this superiority of RAS blockade over other antihypertensive agents relates to the inhibition of angiotensin-II-mediated effects or to the adverse metabolic effects of the comparator drugs.3 The mechanisms of the antidiabetic effects of RAS inhibitors are not clearly understood, but relate to both hemodynamic and nonhemodynamic actions, as well as to effects on peripheral insulin resistance and protection of pancreas structure and function.4, 5
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
